

FIG. 1




FIG. 2






FIG. 3


A



B



C



D




FIG. 4





FIG. 5

FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10


A. 83A10-TCB

Pur. methods: PA + SEC
Purity: <30%
Yield: 6.7 mg/L
Amount: 2.7 mg
Monomer: 82.8%



B. 83A10-TCB

Pur. methods: PA + SEC +
cIEX + re-SEC
Purity: 93.4%
Yield: 0.42 mg/L
Amount: 0.168 mg
Monomer: 82.8%



C. 83A10-TCBcv

Pur. methods: PA + cIEX +
SEC
Purity: 95.3%
Yield: 3.3 mg/L
Amount: 1.3 mg
Monomer: 100%





FIG. 11

A. 83A10-TCB

Pur. methods: PA
Purity: 61.3%
Yield: 26.2 mg/L
Amount: 24.3 mg
Monomer: 63.7%
LC-MS: n. d.



B. 83A10-TCBcv

Pur. methods: PA
Purity: 81.0%
Yield: 51.5 mg/L
Amount: 50.2 mg
Monomer: 68.2%
LC-MS: n. d.





FIG. 11

C. 83A10-TCB

Pur. methods: PA + SEC
Purity: 69.5%
Yield: 14.1 mg/L
Amount: 13.1 mg
Monomer: 74.7%
LC-MS: 40-60%
correct molecule



D. 83A10-TCBcv

Pur. methods: PA + SEC
Purity: 91.0%
Yield: 10.3 mg/L
Amount: 10.0 mg
Monomer: 83.9%
LC-MS: 90%
correct molecule





FIG. 11

E. 83A10-TCB

Pur. methods: [(PA + SEC
+ (PA))] + cIEX + SEC
Purity: 43.1%
Yield: 0.43 mg/L
Amount: 0.73 mg
Monomer: 98.3%
LC-MS: 60-70%
correct molecule



F. 83A10-TCBcv

Pur. methods: [(PA + SEC
+ (PA))] + cIEX + SEC
Purity: 96.2%
Yield: 0.64 mg/L
Amount: 1.27 mg
Monomer: 98.9%
LC-MS: >95%
correct molecule






FIG. 12

A



B



--△-- 83A10 TCB

--▽-- DP47 TCB


○ cells + 2nd IgG

13/49

FIG. 13

A

—○— 83A10 TCBcv (6515)
 --○-- cells



14/49

FIG. 13

B






FIG. 14

A





FIG. 14

B

 17A5 TCB cv (2a)
 cells only




17/49

FIG. 15

18/49

A



B





FIG. 16

19/49

A



B




FIG. 17




FIG. 18





FIG. 18 - 1




FIG. 18 - 1





FIG. 18 - 2

FIG. 18 - 2




FIG. 18 - 2





FIG. 18 - 3

FIG. 18 - 3




FIG. 18 - 4




FIG. 18 - 4





FIG. 19

31/49

A



B




FIG. 20

A




FIG. 20

B

- 83A10 TCB wild type (6598)
- ▨-- 83A10 TCB charged variant (6599)
- cells alone






FIG. 20

C



D






FIG. 20

E



F



35/49

FIG. 21





FIG. 22

37/49


A

Patient 001



B

Patient 002



C

Patient 003




FIG. 23

38/49




FIG. 23

39/49





FIG. 23

40/49





FIG. 23

41/49





FIG. 24




FIG. 25




FIG. 26

Concentrations of 83A10-TCBcv
in cynomolgus monkey post single IV injection




FIG. 27




FIG. 28A




FIG. 28B




FIG. 29

48/49




FIG. 30

